Variant position: 161 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 664 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LNSKEAALSTALSEKRTLEG ELHDLRGQVAKLEAALGEAKK
Mouse LNSKEAALSTALSEKRTLEG ELHDLRGQVAKLEAALGEAKK
Rat LNSKEAALSTALSEKRTLEG ELHDLRGQVAKLEAALGEAKK
Pig LNSKEAALSTALSEKRTLEG ELHDLRGQVAKLEAALGEAKK
Chicken LNSKEAALSTALGEKRNLEN EVRDLRAQVAKLEGALSEAKK
Xenopus laevis LNSKDAALTTALGEKRNLEN EIRELKAHIAKLEASLADTKK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 661 Prelamin-A/C
1 – 646 Lamin-A/C
31 – 387 IF rod
81 – 218 Coil 1B
155 – 155 N6-acetyllysine
171 – 171 N6-acetyllysine; alternate
171 – 171 N6-succinyllysine; alternate
171 – 171 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
65 – 218
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations.
Sebillon P.; Bouchier C.; Bidot L.D.; Bonne G.; Ahamed K.; Charron P.; Drouin-Garraud V.; Millaire A.; Desrumeaux G.; Benaiche A.; Charniot J.-C.; Schwartz K.; Villard E.; Komajda M.;
J. Med. Genet. 40:560-567(2003)
Cited for: VARIANT CMD1A LYS-161;
Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy.
Millat G.; Bouvagnet P.; Chevalier P.; Sebbag L.; Dulac A.; Dauphin C.; Jouk P.S.; Delrue M.A.; Thambo J.B.; Le Metayer P.; Seronde M.F.; Faivre L.; Eicher J.C.; Rousson R.;
Eur. J. Med. Genet. 54:E570-E575(2011)
Cited for: VARIANTS CMD1A PHE-92; LYS-161; LYS-317 AND ARG-523;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.